Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 6, 2018 - Issue 1
Journal homepage
1,043
Views
3
CrossRef citations to date
0
Altmetric
Original Research Article

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration

Szymon JarosławskiPublic Health Department – Research Unit EA 3279, Aix – Marseille University, Marseille, FranceView further author information
,
Pascal AuquierPublic Health Department – Research Unit EA 3279, Aix – Marseille University, Marseille, FranceView further author information
,
Borislav BorissovPrescriptia Ltd, Sofia, BulgariaView further author information
,
Claude DussartLaboratoire Parcours Santé Systémique EA 4129, Claude Bernard University, Lyon, France;Faculté de Médecine Laennec, Université de Lyon, Lyon, FranceView further author information
&
Mondher ToumiPublic Health Department – Research Unit EA 3279, Aix – Marseille University, Marseille, FranceCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7939-7204View further author information
ORCID Icon
Article: 1433426 | Received 06 Oct 2017, Accepted 12 Jan 2018, Published online: 12 Feb 2018

References

  • Avorn J, Shrank W. Highlights and a hidden hazard–the FDA’s new labeling regulations. N Engl J Med. 2006;354:1–8.
  • U.S. Food and Drug Administration. US food and drug administration guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Rockville (MD): Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2009.
  • Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14:967–977.
  • Gnanasakthy A, Mordin M, Clark M, et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value in Health. 2012;15:437–442.
  • Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims US food and drug administration. Rockville, MD: U.S. Food and Drug Administration; 2009.
  • Provost GP. “Homeless” or “orphan” drugs. Am J Hosp Pharm. 1968;25:609.
  • Orphan Drug Act. US food and drug administration.  Rockville, MD; 1983.
  • Brundage M, Bass B, Davidson J, et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2011;20:653–664.
  • Gnanasakthy A, Mordin M, Haydysch E, et al. FDA patient-reported outcome labeling of novel therapies (2011-2015). Value in Health. 2016;19:A285–A86.
  • Clark M, Simons C, Haydysch E, et al. A review of patient-reported outcome orphan drug labels in the United States from January 2006–September 2013: analysis of evidence for orphan drug pro label claims. Value Health. 2014;17:A166.
  • Basch E, Bennett AV. Patient-reported outcomes in clinical trials of rare diseases. J Gen Intern Med. 2014;29(Suppl 3):S801–3.
  • Leidy NK. Addressing content validity of PRO measures: the unique case of rare diseases. In: EveryLife foundation, workshop 2: clinical evaluation of rare disease treatments; 2011 Jun 14–15; Washington (DC).  Novato, CA: EveryLife Foundation for Rare Diseases.
  • Eurordis position paper. WHY research on rare diseases. Paris, France: Eurordis; 2010.
  • The Voice of the Patient. A series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative pulmonary arterial hypertension. Rockville, MD: U.S. Food and Drug Administration; 2014.
  • Adempas. Highlights of prescribing information.: U.S. Food and Drug Administration (FDA). Rockville, MD: Adempas; 2013.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.